Videssa Breast assay not hindered by tissue density
NEW YORK—At this year’s Human Proteome Organization World Congress, Provista Diagnostics Inc. President and CEO Dr. David Reese presented a poster regarding how breast density affects cancer detection. Provista has found that increased breast density does not impact the performance of its Videssa Breast biomarker assay. Previous studies demonstrated the effect in women ages 25 to 50, and the most recent study confirmed the results in mostly post-menopausal women (ages 50 to 75).
“Particularly because the test results are unaffected by dense breast tissue, this assay is an important advancement in proteomic technologies for addressing the many challenges clinicians face in detecting breast cancer in their patients,” said Reese.